Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional, Prospective Study to Evaluate the Effectiveness of Risankizumab in Patients With Recent Diagnosis of Moderate Plaque Psoriasis in a Real Life Setting in Greece- the REDEFINE Study

NCT06247319 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06247319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06247319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional, Prospective Study to Evaluate the Effectiveness of Risankizumab in Patients With Recent Diagnosis of Moderate Plaque Psoriasis in a Real Life Setting in Greece- the REDEFINE Study
Lead sponsor
AbbVie
Phase
Observational
Overall status
Active, not recruiting
Start date
April 29, 2024
Completion date
October 31, 2027
Enrollment
250 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

moderate plaque psoriasis, moderate psoriasis, psoriasis